Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
1412.4(c) 1413.8(c) 1409.6(c) 1416(c) 1399.8(c) Last
8 536 900 5 651 130 3 516 830 2 953 767 3 893 242 Volume
-0.11% +0.10% -0.30% +0.45% -1.14% Change
More quotes
Estimated financial data (e)
Sales 2021 33 019 M 45 625 M 45 625 M
Net income 2021 3 385 M 4 677 M 4 677 M
Net Debt 2021 21 463 M 29 658 M 29 658 M
P/E ratio 2021 20,4x
Yield 2021 5,71%
Sales 2022 34 852 M 48 159 M 48 159 M
Net income 2022 4 327 M 5 979 M 5 979 M
Net Debt 2022 20 136 M 27 824 M 27 824 M
P/E ratio 2022 16,2x
Yield 2022 4,08%
Capitalization 70 047 M 96 813 M 96 792 M
EV / Sales 2021 2,77x
EV / Sales 2022 2,59x
Nbr of Employees 94 066
Free-Float 92,3%
More Financials
Company
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Ratings of GlaxoSmithKline plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GLAXOSMITHKLINE PLC
03:01pBIONTECH : Plans Development of First mRNA-Based Malaria Vaccine
MT
12:38pGLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
PU
11:53aGLAXOSMITHKLINE : BioNTech aims to develop mRNA-based malaria vaccine
RE
10:16aGLAXOSMITHKLINE : Wins US FDA Approval for Shingrix for Shingles Prevention in I..
MT
10:00aASTRAZENECA : BioNTech aims to develop mRNA-based malaria vaccine
RE
09:38aGLAXOSMITHKLINE : Shingrix approved in the US for prevention of shingles in immu..
PU
08:13aGlaxoSmithKline Gets FDA Approval for Shingles Vaccine
DJ
02:11aGLAXOSMITHKLINE : Increases US Shipment of Flu Vaccine Doses to Record High Amid..
MT
07/23GLAXOSMITHKLINE : Kicks Off Influenza Vaccine Delivery to US for 2021-22 Season
MT
07/23GLAXOSMITHKLINE : Board Committee Changes (Form 6-K)
PU
07/23GlaxoSmithKline plc Appoints Anne Beal as a Member of the Audit & Risk Commit..
CI
07/22MARKET CHATTER : Swiss Life to Bid for German Biotech-Focused Industrial Park
MT
07/22GlaxoSmithKline Defies Elliott Management's Demand
CI
07/22QYOU MEDIA : Q India Signs on Nestle As New Advertiser
MT
07/22GlaxoSmithKline Rejects Elliott Management's Demand to Review its Leadership
CI
More news
News in other languages on GLAXOSMITHKLINE PLC
10:35aBEURSAGENDA : buitenlandse fondsen
10:33aGlaxosmithkline erhält weitere FDA-Zulassung für Gürtelrose-Impfstoff
10:23aGLAXOSMITHKLINE : la FDA approuve le vaccin anti-zona
10:03aBioNTech plant Malaria-Impfstoff und Produktionsanlagen in Afrika
07/25BEURSAGENDA : buitenlandse fondsen
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 14,00 GBX
Average target price 1 518,63 GBX
Spread / Average Target 10 749%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC5.51%98 364
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246